# US 2021/0275507 A1 · Methods of treating hepatic encephalopathy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275507 A1
- Document ID: US20210275507A1
- Status: Published application
- Kind: A1
- Application number: 17/213,678
- Filed: 2021-03-26
- Published: 2021-09-09
- Earliest claimed: 2008-10-02
- Assignees: Salix Pharmaceuticals, Inc.
- Applicants: Salix Pharmaceuticals, Inc.
- Inventors: William Forbes
- Web page: https://patentgrep.com/patent/US20210275507A1

## CPC

- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/08: acyclic, e.g. paraformaldehyde
- A61K 31/395: having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K 31/4164: 1,3-Diazoles
- A61K 31/426: 1,3-Thiazoles
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/606: having amino groups
- A61K 31/7016: Disaccharides, e.g. lactose, lactulose (lactobionic acid A61K31/7032)
- A61K 31/785: Polymers containing nitrogen
- A61K 38/14: Peptides containing saccharide radicals; Derivatives thereof {, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin}
- A61K 38/31: Somatostatins
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/12: Antidiarrhoeals
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin.

## Claims

### Claim at position 1

1-96. (canceled)

### Claim 97

A method of increasing the time to development of spontaneous bacterial peritonitis (SBP) in a hepatic encephalopathy patient, comprising administering to the subject 550 mg of rifaximin to the subject two times per day (BID).

### Claim 98 (depends on 97)

The method of claim 97, further comprising administering lactulose.

### Claim 99 (depends on 97)

The method of claim 97, wherein the subject has a Model for End-Stage Liver Disease (MELD) level between 1 and 24.

### Claim 100 (depends on 97)

The method of claim 97, wherein the subject has a Model for End-Stage Liver Disease (MELD) level less than or equal to ten.

### Claim 101 (depends on 97)

The method of claim 97, wherein the subject has a Model for End-Stage Liver Disease (MELD) level between 11 and 18.

### Claim 102 (depends on 97)

The method of claim 97, wherein the subject has a Model for End-Stage Liver Disease (MELD) level between 19 and 24.

### Claim 103 (depends on 97)

The method of claim 97, wherein the subject has a Conn score of 0 or 1.

### Claim 104 (depends on 97)

The method of claim 97, wherein administration of the rifaximin reduces hospitalization frequency by from between about 13% to about 69%.

### Claim 105 (depends on 97)

The method of claim 97, wherein there is a decrease in blood ammonia concentration from baseline after administration of the rifaximin to the subject.

### Claim 106 (depends on 97)

The method of claim 97, wherein there is an increase in critical flicker frequency values from baseline after administration of the rifaximin to the subject.
